**About the Editors**

**Richard Moriggl** studied biotechnology in Germany and completed his Ph.D. in 1997 working on cytokine signaling with Prof. Groner at the Friedrich Miescher Institute, Basel, Switzerland and the Institute of Experimental Cancer Research, Freiburg, Germany. After a postdoctoral fellowship with Prof. Ihle in the area of immunology at St. Jude Children's Research Hospital in Memphis, USA, he undertook a second postdoc in 2000 to work on leukemia with Prof. Beug at the Institute for Molecular Pathology, Vienna. Dr. Moriggl served for 14 years as director of the Ludwig Boltzmann Institute for Cancer Research, heading six research groups that all progressed to tenure tracked positions and integrated into medical research performing universities in Austria. The Moriggl lab explores targeting of STAT transcription factors and performs basic and translational cancer research with a main focus on generation and utilization of gene-targeted mouse models. Established cellular systems are used to investigate neoplastic T-cell development in PTCL and how these processes can be blocked. The Moriggl lab contributes to the understanding of gene regulatory and chromatin landscape consequences in cancer upon hyperactivation of JAK-STAT3/5 action. Unpublished work investigates T-cell development and targeting STAT5 to understand cancer progression in association with fatal clinical problems.

**Patrick T. Gunning** is a full professor of chemistry and Canada Research Chair in Medicinal Chemistry at the University of Toronto. Dr. Gunning received his BSc (2001) and Ph.D. (2005) from the University of Glasgow before pursuing postdoctoral studies with Professor Andrew D. Hamilton (Yale University). His research group is focussed on the development of small molecule inhibitors of protein-protein interactions, namely disruptors of STAT3 and STAT5 proteins, HDAC inhibitors, and monovalent degradation. In this field, Dr. Gunning has co-authored >100 research publications and received numerous awards and honours. These include the 2015 Rose Winer Levin Lectureship by Dana-Farber Cancer Institute, the 2012 RSC MedChemComm Emerging Investigator Lectureship by the Royal Society for Chemistry (UK), the 2016 Canadian Society for Chemistry's Bernard Belleau award (Canada) and named in Canada's Top 40 under 40 awardees.

**Gy ¨orgy Mikl ´os Keser ¨u** obtained his Ph.D. at Budapest, Hungary. He worked for Sanofi and in 1999 moved to Gedeon Richter. Since 2007 he was appointed as the Head of Discovery Chemistry at Gedeon Richter. He was involved in the discovery of 10 clinical candidates (41 patent applications) entered into clinical development in neurological and psychiatric indications. He contributed to the discovery of the antipsychotic Vraylar-<sup>R</sup> (US)/ Reagila-<sup>R</sup> (EU) that has been approved by the US FDA in 2015 and European authorities in 2017. He served as a director general of the Research Centre for Natural Sciences (RCNS) at the Hungarian Academy of Sciences. He played a significant role in the development of physicochemical profiling in drug discovery, the concept of compound quality and the improvement of optimization strategies in medicinal chemistry. His results has been acknowledged by the George A. Olah Award and the Prous Institute Overton and Meyer Award of the European Federation of Medicinal Chemistry. From 2015 he is a full professor at the Budapest University of Technology and Economics and heading the Medicinal Chemistry Research Group at RCNS. In 2019 he has been elected as corresponding member of the Hungarian Academy of Sciences. His research interests include medicinal chemistry and drug design. He has published over 200 papers and more than 10 books and book chapters.
